	US 12,234,260 B2
	Virus-like nanoparticles for oral delivery
R. Holland Cheng, Oakland, CA (US); Chun Chieh Chen, Oakland, CA (US); Mohammad Ali Baikoghli, Oakland, CA (US); and Marie Stark, Oakland, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Sep. 27, 2022, as Appl. No. 17/935,682.
Application 17/935,682 is a continuation of application No. 15/734,877, granted, now 11,466,055, previously published as PCT/US2019/035823, filed on Jun. 6, 2019.
Claims priority of provisional application 62/681,637, filed on Jun. 6, 2018.
Prior Publication US 2023/0159596 A1, May 25, 2023
Int. Cl. C07K 14/005 (2006.01); A61K 33/242 (2019.01); C07K 14/00 (2006.01); C07K 14/02 (2006.01); C07K 14/08 (2006.01); C07K 14/62 (2006.01); C12N 7/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/005 (2013.01) [C07K 14/62 (2013.01); C12N 7/00 (2013.01); A61K 38/00 (2013.01); C12N 2770/28122 (2013.01); C12N 2770/28123 (2013.01)]

19 Claims

1. A composition comprising:

(i) a modified capsid protein comprising a portion of hepatitis E virus (HEV) open Reading Frame 2 (ORF2) protein, wherein at least one amino acid in the 342-344, 402-408, 510-514, 493-498, 570-579, 529-536, or 520-525 segment of the HEV ORF2 protein amino acid sequence set forth in SEQ ID NO: 1 or the corresponding segment of SEQ ID NO:2, 3, 4, 5, or 6 is replaced with a cysteine, which is conjugated with a nanocluster of an element selected from Groups 3 through 18 having an atomic number greater than 20, wherein the nanocluster is about 2-3 nm horizontally and about 2 nm vertically from the cysteine; and

(ii) a bioactive agent encapsulated in an HEV virus-like particle (VLP) formed by the modified capsid protein.